Information on director who purchased the shares as per 2018 annual report:
Name: Dr Chris Roberts AO
Title: Non-Executive Chairman
Qualifications: BE(Hons), MBA, PhD, Hon DSc(Macq), Hon DSc(UNSW), FTSE, FAICD, HonFIEAust
Experience and expertise: Dr Roberts AO is a highly experienced director and senior executive with over 41years’ experience in the medical innovation space. He was CEO/President ofCochlear Limited (ASX: COH) from February 2004 to August 2015. He was alsoChairman of Sirtex Medical Ltd (ASX: SRX), from March 2000 to December 2002,and was Executive Vice-President of global sleep disorder treatment companyResMed Inc (NYSE: RMD, ASX: RMD) from 1992 to 2004. He is a PLuS AllianceProfessor appointed across 3 universities: UNSW, King’s College London andArizona State University. Dr Roberts AO also sits on the boards of a number of otherentities and groups including; Clarity Pharmaceuticals Limited, Innovation ScienceAustralia, Biomedical Translation Fund, Jobs for NSW and O’Connell StreetAssociates.
Other current directorships: ResMed Inc. (NYSE: RMD, ASX: RMD)
Former directorships (last 3 years): Cochlear Limited (ASX: COH) (resigned on 31 August 2015)
Special responsibilities: Member of the Nomination and Remuneration Committee and member of Audit andRisk Committee
Interests in shares: 11,125,000 ordinary shares
OSL Price at posting:
6.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)